Quidel Unveils Name of Pending POC MDx Platform; Restructures Licensing Deal for Key Tech
October 27, 2011
Quidel Unveils Name of Pending POC MDx Platform; Restructures Licensing Deal for Key Tech
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Quidel Continues to Advance Trio of MDx Initiatives; On Target to Complete All by End of '13
March 1, 2012 / PCR Insider - Quidel Obtains CE Mark for AmpliVue C. Difficile, Company's First Handheld MDx Test
March 29, 2012 / PCR Insider - With BioHelix Acquisition, Quidel Brings Isothermal Amplification Tech in House
May 9, 2013 / PCR Insider - Australian OEM Firm Axxin Readying Readers for Partners' Isothermal Amplification MDx Tests
May 3, 2012 / PCR Insider - BioHelix Gets FDA Nod for First Point-of-Care MDx Test
October 20, 2011 / PCR Insider